The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge

BACKGROUND: Interleukin 13 (IL13) is a T-helper type 2 (Th2) cytokine associated with inflammation and pathology in allergic diseases such as bronchial asthma. We have shown that treatment with lebrikizumab, an anti-IL13 monoclonal antibody, significantly improves prebronchodilator forced expiratory...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheerens, H, Arron, J R, Zheng, Y, Putnam, W S, Erickson, R W, Choy, D F, Harris, J M, Lee, J, Jarjour, N N, Matthews, J G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204278/
https://www.ncbi.nlm.nih.gov/pubmed/24131304
http://dx.doi.org/10.1111/cea.12220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204278/
https://www.ncbi.nlm.nih.gov/pubmed/24131304
http://dx.doi.org/10.1111/cea.12220

Ejemplares similares